c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Athanasiou A, Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Liloglou T, Karameris A, Foukas P, Manolis EN, Field JK, Kittas C.
Athanasiou A, et al.
Histopathology. 2000 Jul;37(1):45-54. doi: 10.1046/j.1365-2559.2000.00898.x.
Histopathology. 2000.
PMID: 10931218